Skip to main content
Erschienen in: Clinical Rheumatology 6/2017

10.03.2017 | Brief Report

Autoantibodies to types I and IV collagen and heart valve disease in systemic lupus erythematosus/antiphospholipid syndrome

verfasst von: José Pardos-Gea, Josefina Cortés-Hernández, Jesus Castro-Marrero, Eva Balada, José Ordi-Ros

Erschienen in: Clinical Rheumatology | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

Introduction/objectives autoantibodies to types I and IV collagen have been described in rheumatic fever and infective endocarditis. We tried to elucidate if an autoimmune response against collagens I and IV exists, associated with heart valve disease in systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). A cohort of 172 patients with SLE (n = 79), primary APS (PAPS, n = 83), and secondary APS (n = 10) were assessed for valvulopathy by transthoracic echocardiograms. Autoantibodies to types I and IV collagen were assessed in patients and 50 controls, setting autoantibody positivity at two standard deviations above the mean antibody level of controls. Positive anticollagen IV antibody rate was significantly higher in SLE patients (17.7%) in respect to the rest of groups (PAPS 2.4%, controls 2%; P = 0.001). Percentage of positive autoantibodies to collagen I was similar in SLE and APS cohort of patients with and without valvular disease (48.4 vs 51.6%, respectively; P = 0.45). Percentage of positive autoantibodies to collagen IV was increased but not significantly in SLE and APS cohort of patients with respect to those without valvular disease (62.5 vs 37.5%, respectively; P = 0.08). Mean (standard deviation) levels of positive anticollagen I and IV antibodies did not differ between patients with and without valvular disease (85.6 ± 55 vs 81 ± 85 U/ml, respectively; P = 0.86 for anticollagen I) (0.05 ± 0.02 vs 0.12 ± 0.16 U/ml, respectively; P = 0.34 for anticollagen IV). Our data indicate a lack of association of autoantibodies to types I and IV collagen with heart valve disease in SLE and APS.
Literatur
1.
Zurück zum Zitat Libman E, Sacks B (1924) A hitherto undescribed form of valvular and mural endocarditis. Arch Intern Med 33:701–737CrossRef Libman E, Sacks B (1924) A hitherto undescribed form of valvular and mural endocarditis. Arch Intern Med 33:701–737CrossRef
2.
Zurück zum Zitat Cervera R, Tektonidou MG, Espinosa G et al. (2011) Task force on catastrophic antiphospholipid syndrome (APS) and non-criteria APS manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions. Lupus. Feb;20(2):165–73. Cervera R, Tektonidou MG, Espinosa G et al. (2011) Task force on catastrophic antiphospholipid syndrome (APS) and non-criteria APS manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions. Lupus. Feb;20(2):165–73.
3.
Zurück zum Zitat Shapiro RF, Gamble CN, Wiesner KB, Castles JJ, Wolf AW, Hurley EJ, Salel AF et al (1977) Immunopathogenesis of Libman-Sacks endocarditis: assessment by light and immunofluorescent microscopy in two patients. Ann Rheum Dis 36(6):508–516CrossRefPubMedPubMedCentral Shapiro RF, Gamble CN, Wiesner KB, Castles JJ, Wolf AW, Hurley EJ, Salel AF et al (1977) Immunopathogenesis of Libman-Sacks endocarditis: assessment by light and immunofluorescent microscopy in two patients. Ann Rheum Dis 36(6):508–516CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Bidani AK, Roberts JL, Schwartz MM, Lewis EJ (1980) Immunopathology of cardiac lesions in fatal systemic lupus erythematosus. Am J Med 69(6):849–858CrossRefPubMed Bidani AK, Roberts JL, Schwartz MM, Lewis EJ (1980) Immunopathology of cardiac lesions in fatal systemic lupus erythematosus. Am J Med 69(6):849–858CrossRefPubMed
5.
Zurück zum Zitat Ziporen L, Goldberg I, Arad M et al (1996) Libman-Sacks endocarditis in the antiphospholipid syndrome: immunopathologic findings in deformed heart valves. Lupus 5:196–205CrossRefPubMed Ziporen L, Goldberg I, Arad M et al (1996) Libman-Sacks endocarditis in the antiphospholipid syndrome: immunopathologic findings in deformed heart valves. Lupus 5:196–205CrossRefPubMed
6.
Zurück zum Zitat Afek A, Schoenfeld Y, Manor R et al (1999) Increased endothelial cell expression of α3ß1 integrin in cardiac valvulopathy in primary (Hughes) and secondary antiphospholipid syndrome. Lupus 8:502–507CrossRefPubMed Afek A, Schoenfeld Y, Manor R et al (1999) Increased endothelial cell expression of α3ß1 integrin in cardiac valvulopathy in primary (Hughes) and secondary antiphospholipid syndrome. Lupus 8:502–507CrossRefPubMed
7.
Zurück zum Zitat Weber KT (1989) Cardiac interstitium in health and disease: the fibrillar collagen network. J Am Coll Cardiol 13(7):1637–1652CrossRefPubMed Weber KT (1989) Cardiac interstitium in health and disease: the fibrillar collagen network. J Am Coll Cardiol 13(7):1637–1652CrossRefPubMed
8.
Zurück zum Zitat Martins TB, Hoffman JL, Augustine NH et al (2008) Comprehensive analysis of antibodies responses to streptococcal and tissue antigens in patients with acute rheumatic fever. Int Immunol 20(39):445–452CrossRefPubMed Martins TB, Hoffman JL, Augustine NH et al (2008) Comprehensive analysis of antibodies responses to streptococcal and tissue antigens in patients with acute rheumatic fever. Int Immunol 20(39):445–452CrossRefPubMed
9.
Zurück zum Zitat De Buyzere ML, De Scheerder IK, Delanghe JR, Robbrecht JH, Clement DL, Wieme RJ (1989) Measurement of autoimmune response against collagen types I, III, and IV by ELISA, and its application in infective endocarditis. Clin Chem 35(2):246–250PubMed De Buyzere ML, De Scheerder IK, Delanghe JR, Robbrecht JH, Clement DL, Wieme RJ (1989) Measurement of autoimmune response against collagen types I, III, and IV by ELISA, and its application in infective endocarditis. Clin Chem 35(2):246–250PubMed
10.
Zurück zum Zitat Miyakis S, Lockshin MD, Atsumi T et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295–306CrossRefPubMed Miyakis S, Lockshin MD, Atsumi T et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295–306CrossRefPubMed
11.
Zurück zum Zitat Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725CrossRefPubMed Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725CrossRefPubMed
12.
Zurück zum Zitat Pardos-Gea J, Ordi-Ros J, Avegliano G et al (2010) Echocardiography at diagnosis of antiphospholipid syndrome provides prognostic information on valvular disease evolution and identifies two subtypes of patients. Lupus 19:575–582CrossRefPubMed Pardos-Gea J, Ordi-Ros J, Avegliano G et al (2010) Echocardiography at diagnosis of antiphospholipid syndrome provides prognostic information on valvular disease evolution and identifies two subtypes of patients. Lupus 19:575–582CrossRefPubMed
13.
Zurück zum Zitat Choi EK, Gatenby PA, McGill NW, Bateman JF, Cole WG, York JR (1988) Autoantibodies to type II collagen: occurrence in rheumatoid arthritis, other arthritides, autoimmune connective tissue disease, and chronic inflammatory syndromes. Annals of the Rheumatic Disease 47:313–322CrossRef Choi EK, Gatenby PA, McGill NW, Bateman JF, Cole WG, York JR (1988) Autoantibodies to type II collagen: occurrence in rheumatoid arthritis, other arthritides, autoimmune connective tissue disease, and chronic inflammatory syndromes. Annals of the Rheumatic Disease 47:313–322CrossRef
14.
Zurück zum Zitat Stuart JM, Huffstutter EH, Townes AS, Kang AH (1983) Incidence and specificity of antibodies to types I, II, III, IV, and V collagen in rheumatoid arthritis and other rheumatic disease as measured by I 125-radioimmunoassay. Arthritis Rheum 26:832–840CrossRefPubMed Stuart JM, Huffstutter EH, Townes AS, Kang AH (1983) Incidence and specificity of antibodies to types I, II, III, IV, and V collagen in rheumatoid arthritis and other rheumatic disease as measured by I 125-radioimmunoassay. Arthritis Rheum 26:832–840CrossRefPubMed
15.
Zurück zum Zitat Cook AD, Rowley MJ, Wines BD, Mackay IR (1994) Antibodies to the collagen-like region of C1q and type II collagen are independent non-cross-reactive populations in systemic lupus erythematosus and rheumatoid arthritis. J Autoimmun 7(3):369–378CrossRefPubMed Cook AD, Rowley MJ, Wines BD, Mackay IR (1994) Antibodies to the collagen-like region of C1q and type II collagen are independent non-cross-reactive populations in systemic lupus erythematosus and rheumatoid arthritis. J Autoimmun 7(3):369–378CrossRefPubMed
16.
Zurück zum Zitat Cook AD, Mackay IR, Cicuttini FM, Rowley MJ (1997) IgG subclasses of antibodies to type II collagen in rheumatoid arthritis differ from those in systemic lupus erythematosus and other connective tissue diseases. J Rheumatol 24(11):2090–2096PubMed Cook AD, Mackay IR, Cicuttini FM, Rowley MJ (1997) IgG subclasses of antibodies to type II collagen in rheumatoid arthritis differ from those in systemic lupus erythematosus and other connective tissue diseases. J Rheumatol 24(11):2090–2096PubMed
17.
Zurück zum Zitat Manivel VA, Sohrabian A, Wick MC, Mullazehi M, Håkansson LD, Rönnelid J (2015) Anti-type II collagen immune complex-induced granulocyte reactivity is associated with joint erosions in RA patients with anti-collagen antibodies. Arthritis Res Ther 17:8CrossRefPubMedPubMedCentral Manivel VA, Sohrabian A, Wick MC, Mullazehi M, Håkansson LD, Rönnelid J (2015) Anti-type II collagen immune complex-induced granulocyte reactivity is associated with joint erosions in RA patients with anti-collagen antibodies. Arthritis Res Ther 17:8CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Cui Z, Zhao MH, Jia XY, Wang M, Hu SY, Wang SX, Yu F, Brown KL, Hudson BG, Pedchenko V (2016) Antibodies to α5 chain of collagen IV are pathogenic in Goodpasture’s disease. J Autoimmun 70:1–11CrossRefPubMed Cui Z, Zhao MH, Jia XY, Wang M, Hu SY, Wang SX, Yu F, Brown KL, Hudson BG, Pedchenko V (2016) Antibodies to α5 chain of collagen IV are pathogenic in Goodpasture’s disease. J Autoimmun 70:1–11CrossRefPubMed
19.
Zurück zum Zitat Petty RE, Hunt DW, Rosenberg AM (1986) Antibodies to type IV collagen in rheumatic diseases. J Rheumatol 13(2):246–253PubMed Petty RE, Hunt DW, Rosenberg AM (1986) Antibodies to type IV collagen in rheumatic diseases. J Rheumatol 13(2):246–253PubMed
20.
Zurück zum Zitat Mackel AM, de Lustro F, Harper FE, Le Roy EC (1982) Antibodies to collagen in scleroderma. Arthritis Rheum 25:522–531CrossRefPubMed Mackel AM, de Lustro F, Harper FE, Le Roy EC (1982) Antibodies to collagen in scleroderma. Arthritis Rheum 25:522–531CrossRefPubMed
21.
Zurück zum Zitat Moreland LW, Gay RE, Gay S (1991) Collagen autoantibodies in patients with vasculitis and systemic lupus erythematosus. Clin Immunol Immunopathol 60(3):412–418CrossRefPubMed Moreland LW, Gay RE, Gay S (1991) Collagen autoantibodies in patients with vasculitis and systemic lupus erythematosus. Clin Immunol Immunopathol 60(3):412–418CrossRefPubMed
22.
Zurück zum Zitat Fukasawa Y, Kano S (1993) Anti-type II collagen antibodies in collagen disease. Rinsho Byori 41(8):876–881PubMed Fukasawa Y, Kano S (1993) Anti-type II collagen antibodies in collagen disease. Rinsho Byori 41(8):876–881PubMed
23.
Zurück zum Zitat Sjoholm AG, Martensson U, Sturfelt G (1997) Serial analysis of autoantibody responses to the collagen-like region of Clq, collagen type II, and double stranded DNA in patients with systemic lupus erythematosus. J Rheumatol 24(5):871–878PubMed Sjoholm AG, Martensson U, Sturfelt G (1997) Serial analysis of autoantibody responses to the collagen-like region of Clq, collagen type II, and double stranded DNA in patients with systemic lupus erythematosus. J Rheumatol 24(5):871–878PubMed
24.
Zurück zum Zitat Blank M, Krause I, Magrini L et al (2006) Overlapping humoral autoimmunity links rheumatic fever and the antiphospholipid syndrome. Rheumatology 45:833–841CrossRefPubMed Blank M, Krause I, Magrini L et al (2006) Overlapping humoral autoimmunity links rheumatic fever and the antiphospholipid syndrome. Rheumatology 45:833–841CrossRefPubMed
Metadaten
Titel
Autoantibodies to types I and IV collagen and heart valve disease in systemic lupus erythematosus/antiphospholipid syndrome
verfasst von
José Pardos-Gea
Josefina Cortés-Hernández
Jesus Castro-Marrero
Eva Balada
José Ordi-Ros
Publikationsdatum
10.03.2017
Verlag
Springer London
Erschienen in
Clinical Rheumatology / Ausgabe 6/2017
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-017-3594-9

Weitere Artikel der Ausgabe 6/2017

Clinical Rheumatology 6/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.